Novi lekovi u terapiji dislipidemija by Novaković, Aleksandra et al.
  
www.medfak.ni.ac.rs/amm 
54 
Review article UDC: 615.272:616-008.83 
doi:10.5633/amm.2018.0109 
 
 
 
 
 
NEW DRUGS FOR THE TREATMENT OF DYSLIPIDEMIA 
 
Aleksandra Novaković1, Marija Marinko1, Ivan Stojanović2,3, 
Dragoslav Nenezić2,3, Predrag Milojević2,3, Vladimir Kanjuh4 
 
 
Dyslipidemia is the leading risk factor for the development of atherosclerosis and 
associated consequences, such as coronary heart disease, ischemic cerebrovascular and 
peripheral vascular disease. These diseases are the major cause of mortality in the world and in 
Europe as well, where they are responsible for around 45% of all deaths. Treatment of 
dyslipidemia includes the use of statins, ezetimibe, fibrates, niacin, bile acids sequestrants and 
omega-3 fatty acids. Although statins play the major role in dyslipidemia treatment by reducing 
the risk of cardiovascular (CV) events by 30%, there is a need for additional new drugs that 
reduce the residual risk even more. PCSK9 inhibitors, apolipoprotein B (apoB) synthesis 
inhibitors, MTP inhibitors and CETP inhibitors are already approved for the specific indications, 
or are in the advanced stages of clinical investigation. Two PCSK9 inhibitors, alirocumab and 
evolocumab are approved for use in combination with statins for the treatment of heterozygous 
familial hypercholesterolemia (FH), but also in patients with clinical atherosclerotic CV diseases 
who require additional low-density lipoprotein cholesterol (LDL-C) level reduction. In addition, 
evolocumab is approved for use in patients with homozygous FH. Mipomersen, apoB synthesis 
inhibitor, lomitapide, and oral MTP inhibitor are currently approved in the treatment of patients 
with homozygous FH as an adjunct to the maximum tolerated doses of statins and other lipid-
lowering drugs. Although the new lipid-lowering agents produce significant LDL-C level 
reduction, more clinical studies are necessary to confirm their efficacy and safety in 
dyslipidemia treatment. 
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Introduction 
 
Dyslipidemia, characterized by increased levels 
of low-density lipoprotein cholesterol (LDL-C) and 
triglycerides, and low levels of high-density lipopro-
tein cholesterol (HDL-C) are the major risk factors 
for the development of atherosclerosis and associa-
ted diseases as well (coronary artery, ischemic cere-
brovascular and peripheral vascular disease). They 
are the major cause of morbidity and mortality among 
middle-aged adults as well as in the elderly (1). 
Statins are the first line drugs used in the 
dyslipidemia treatment. They generally reduce the 
LDL-C level by 25-50% and have a range of pleio-
trophic effects as well. Intestinal cholesterol absorp-
tion inhibitors (ezetimibe) and bile acid sequestrants 
(not registered in Serbia)reduce LDL-C level in com-
bination with statins by 15-20% and 10-20%, res-
pectively. The nicotinic acid acts by HDL-C aug-
mentation (not registered in Serbia), while fibrates 
and omega 3 fatty acids lower triglycerides blood 
level as well. 
According to the European Society of Cardio-
logy (ESC) and the European Atherosclerosis Society 
(EAS), the latest guidelines for dyslipidemia mana-
gement shows that statins are the drugs of choice 
for the treatment of hyperlipoproteinemia. If the goal 
is not reached by the use of statins, the combination 
of statin and ezetimibe, or a bile acid sequestrant, as 
a second line, should be considered as an adjunct. In 
patients with statin intolerance, ezetimibe or bile acid 
sequestrants should be used. In a group of high-risk 
patients, with persistent high LDL-C despite the 
maximal tolerated statin dose, in combination with 
ezetimibe or in patients with statin intolerance, the 
use of a new group of lipid-lowering agents, like 
PCSK9 inhibitors, should be considered (2).  
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It is important to emphasize that in spite of 
statin effectiveness in reducing the risk of CV events 
by 30%, residual risk still remains, indicating that 
there is a need for additional drugs to reduce the 
residual risk further more.  
New drugs for dyslipidemia treatment include 
proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibitors, apolipoprotein B (apoB) synthesis inhibi-
tors, microsomal triglyceride transfer protein (MTP) 
inhibitors and cholesteryl ester transfer protein (CETP) 
inhibitors, that are either already approved for the 
use in specific indications or are in the advanced sta-
ges of clinical investigation. The aim of our work was 
to make an overview of these new groups of drugs in 
the treatment of dyslipidemia with an overview of 
their mechanism of action, adverse effects and resul-
ts of clinical trials, as well as their current place in 
the therapy. 
 
Methods 
 
With a view of collecting data about new lipid-
lowering agents, we used several sources of infor-
mation. Most data were collected by searching a 
large database MEDLINE: 
(http://www.ncbi.nlm.nih.gov/pubmed),  
using the key words "dyslipidemia", "hyperlipidemia" 
and "familial hypercholesterolaemia" in combination 
with "PCSK9 inhibitors" "alirocumab", "evolocumab", 
"mipomersen", "MTP inhibitors", "CETP inhibitors", 
"new drugs" and "clinical trials". In databases, from 
2001-2016, we searched for: review articles relating 
to the new lipid-lowering agents and clinical studies 
which investigated the effectiveness and side effects 
of the new lipid-lowering agents (original articles), as 
well as the latest guidelines for the treatment of 
dyslipidemia. Each paper was reviewed and further 
analyzed. The references of the found articles were 
examined in order to identify additional studies. 
Priority was given to manuscripts published in the 
past 5 years, randomized placebo-controlled trials, 
and meta-analyses. Overall, 7 review papers and 19 
clinical studies were used. 
 
PCSK9 inhibitors 
 
Two PCSK9 inhibitors, alirocumab and evolo-
cumab, are approved for the use in combination with 
statins for the treatment of heterozygous familial 
hypercholesterolemia (FH), as well as in patients 
with clinical atherosclerotic CV diseases who require 
additional LDL-C level reduction (3, 4). Evolocumab 
is also approved for the use in the patients with 
homozygous FH (4). It should be noted that these 
two drugs were registered in the Republic of Serbia, 
evolocumab in December 2016, and alirocumab in 
April 2017. The clinical development program for 
bococizumab was discontinued in November 2016 be-
cause of an unanticipated attenuation of LDL-C lowe-
ring over time, as well as a higher level of immuno-
genicity and higher rate of injection-site reactions 
than are shown with the other agents in this class 
(5). Few different PCSK9 inhibitors (e.g. monoclonal 
antibodies LGT-209, RG-7652) are currently in the 
phase I or II clinical studies (1). 
In October 2016, ESC/EAS Task Force con-
sensus statement for the use of PCSK9 inhibitor 
treatment in patients at very high risk of recurrent 
cardiovascular events with poorly controlled LDL-C 
levels was published. It is recommended that the 
treatment with a PCSK9 inhibitor may be considered 
in very high risk patients with clinical atherosclerotic 
CV diseases, including those with progressive form of 
CV disease or diabetes mellitus (with target organ 
damage or a major CV factor); or in patients with 
severe FH without atherosclerotic CV diseases with 
substantially elevated LDL-C levels despite maximal 
statin/ezetimibe therapy. In addition, patients with 
verified statin intolerance may be also considered for 
treatment with these agents (6). 
PCSK9 is a serine protease that plays a central 
role in cholesterol metabolism in the liver by 
enhancing the degradation of LDL receptors (7, 8). 
Serum level of LDL-C is controlled predominately by 
the hepatic LDL receptors. When LDL-C binds to LDL 
receptor, the complex undergoes endocytosis, thus 
removing LDL-C from the circulation. After releasing 
LDL-C, LDL receptor is then either degraded or 
recycled back to the cell surface (8). Circulating 
PCSK9 binds to the LDL receptors directing them to 
the lysosomes for degradation and preventing the 
receptor recycling process after internalization. By 
inhibiting this protein, PCSK9 inhibitors reduce LDL 
receptors degradation and increase expression of 
LDL receptors resulting in LDL-C level reduction 
(Figure 1) (1, 8). 
 
 
 
 
 
 
Figure 1. Mechanism of action of PCSK9  
(proprotein convertase subtilisin/kexin type 9) 
inhibitors (adapted from reference 1) 
LDL - low-density lipoproteins; LDLR – LDL receptor 
 
 
 
Results of clinical trials have shown that PCSK9 
inhibitors reduce LDL-C level by 50-60% independent 
from the presence of a background therapy with 
statins or other lipid-lowering agents (2). They are 
well tolerated, while the most common adverse effe-
cts include injection site reaction (erythema, pain, 
bruises, itching, swelling), as well as nasopharyngitis, 
upper respiratory tract infections, influenza, back 
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pain, arthralgia, myalgia, nausea. Hypersensitivity 
reactions (e.g., pruritus, rash, urticaria), including 
some serious events, like hypersensitivity vasculitis 
and hypersensitivity reactions requiring hospitaliza-
tion, have been reported with alirocumab treatment. 
These allergic reactions, as well as elevated liver en-
zymes, were the most common causes of alirocumab 
treatment discontinuation. It should be noted that 
small but significant number of neurocognitive effects 
was described, but this finding requires further 
scrutiny. PCSK9 inhibitors are administered subcuta-
neously. The recommended doses for evolocumab 
are 140 mg once every 2 weeks or 420 mg monthly 
(both doses are equivalent), while alirocumab is 
administered from an initial 75 mg to a maximum of 
150 mg every 2 week (or alternatively 300 mg 
monthly). After single-dose subcutaneous administ-
ration, the maximum serum concentrations of evolo-
cumab are reached in 3-4 days, i.e. in 3-7 days after 
administration of alirocumab, while their bioavai-
lability is 72% and 85%, respectively. They are pri-
marily distributed in circulation with limited distribu-
tion in tissues. Metabolism is not investigated as 
proteins (human monoclonal antibodies of the class 
IgG2 (evolocumab) and IgG1 (alirocumab)) are 
expected to degrade to small peptides and individual 
amino acids. The median apparent half-life of evolocu-
mab at steady state was 11 to 17 days, i.e. 17 to 20 
days of alirocumab. Concomitant administration of 
PCSK9 inhibitors with a statin leads to an increase in 
clearance and a decrease in the median apparent 
half-life of PCSK9 inhibitors, but without affecting 
their pharmacodynamic effect and the need for do-
sage adjustment. Also, no dosage adjustments are re-
quired depending on age, sex, race, body weight, nor 
in patients with mild and moderate liver and renal 
impairment (they were not studied in patients with 
severe impairment) (9, 10). 
Until now, PCSK9 inhibitors have been investi-
gated in healthy subjects, patients with statin intole-
rance, patients at high CV risk, as well as in patients 
with FH receiving maximally tolerated statin doses 
(± other lipid-lowering agents) (11). 
Evolocumab has been investigated within 5 
phase II and 7 phase III trials. However, the pro-
blem is that all of them were short-term studies; 
therefore it was necessary to conduct long-term in-
vestigation of evolocumab. Hence, OSLER program, 
that included 4,465 patients, was designed with pri-
mary goal of obtaining the longer-term data on safe-
ty, side-effect profile and LDL-C reduction and also 
included an exploratory analysis on CV outcomes.  
OSLER program consists of two clinical trials 
OSLER 1 and OSLER 2 that included patients who 
had already been involved in a variety of phase II 
and phase III trials that examined evolocumab. 
One group of patients received the evolocu-
mab (140 mg every 2 weeks or 420 mg once a 
month) in combination with statins and other lipid-
lowering agents, while the other group received 
standard therapy (statin or other lipid-lowering age-
nts). The LDL-C level, safety and the incidence of CV 
events (myocardial infarction, stroke, need for reva-
scularization and CV death) were followed during the 
average period of 11.1 months (12). 
The OSLER program results showed that evo-
locumab, when compared with standard therapy, 
reduced the LDL-C level by 61% (p < 0.001), from 
the median baseline of 120 mg/dL to 48.3 mg/dL 
after 12 weeks. This reduction in LDL-C level was 
consistent over 48 weeks. Changes in other athero-
genic lipid fractions were similar, non-HDL-C was 
reduced by 52.0%, apoB by 47.3%, total cholesterol 
by 36.1%, triglycerides by 12.6% and lipoprotein(a) 
(Lp(a)) by 25.5% (p < 0.001 for all comparisons). 
Evolocumab raised levels of HDL cholesterol by 7.0% 
and apolipoprotein A1 (apo A1) by 4.2%, as compa-
red with standard therapy (p < 0.001 for both com-
parisons). There were no differences in the rates of 
overall adverse events, serious adverse events, ele-
vations in AST and ALT (> 3x the upper limit of 
normal) or creatine kinase (> 5x the upper limit of 
normal) levels. However, injection-site reactions, 
neurocognitive adverse events, as well as some non-
specific adverse events, such as arthralgia, head-
ache, fatigue, were reported more frequently in the 
evolocumab group (12). 
The results of particular interest, which should 
be confirmed by additional studies, are those show-
ing that patients in evolocumab group had signifi-
cantly lower rate of all CV events (0.95%) than did 
patients in the standard-therapy group (2.18%) (p = 
0.003) during one year (12). In May 2017, results 
from randomized, double-blind, placebo-controlled 
FOURIER (Further Cardiovascular Outcomes Rese-
arch with PCSK9 Inhibition in Subjects with Elevated 
Risk) trial involving more than 27,500 patients with 
atherosclerotic cardiovascular disease who were re-
ceiving statin therapy, were published. The primary 
efficacy end point was the composite of myocardial 
infarction, stroke, hospitalization for unstable angina, 
coronary revascularization or cardiovascular death, 
and the median duration of follow-up was 2.2 years. 
Patients were randomly assigned to receive evolo-
cumab or matching placebo as an addition to standard 
statin therapy. Results showed that reduction in LDL 
cholesterol levels with evolocumab was from a me-
dian baseline value of 2.4 mmol/l to 0.8 mmol/l and, 
relative to placebo, evolocumab treatment signifi-
cantly reduced the risk (15%) of the primary end 
point (9.8% in evlocumab group vs. 11.3% in place-
bo group, p < 0.001). There was no significant diffe-
rence between the study groups with regard to 
adverse events (including new-onset diabetes and ne-
urocognitive events), with the exception of injection-
site reactions, which were more common with evolo-
cumab (2.1% vs. 1.6%) (13). Secondary analysis of 
this study showed that patients who achieved pro-
gressively lower LDL-C concentrations in the FOURIER 
trial had progressively fewer cardiovascular events 
with no evidence of a plateau and with no increase in 
adverse events. Although most evaluated safety end-
points would be expected to manifest within the 2.2 
years of follow-up, the adverse events such as can-
cer can take longer to manifest. Consequently, two 
long-term extension studies of FOURIER following 
approximately 6,600 patients (NCT03080935 and 
NCT02867813) that are planned to last 5 years 
should provide longer-term insights (14).  
Alirocumab was investigated during 14 phase 
III trials within ODYSSEY program, which included 
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more than 23,500 patients with uncontrolled hyper-
cholesterolemia (those with FH, those at high CV risk 
and those with statin intolerance) (11). 
Most attention was attracted by ODYSSEY 
LONG TERM trial which was aimed to obtain longer-
term data on safety and reduction in LDL-C levels by 
alirocumab, but the data on the incidence of CV 
events was also collected for a post hoc analysis. The 
study included 2,341 patients at high CV risk (patients 
with heterozygous FH with or without documented CV 
disease or patients with hypercholesterolemia and 
documented CV disease) who had LDL-C levels ≥70 
mg/dL (1.8 mmol/L) despite therapy with statins at 
maximally tolerated dose, with or without other lipid-
lowering drugs. Patients received alirocumab 150 mg 
or placebo every 2 weeks for 78 weeks. After 24 
weeks, there was a significant difference in the LDL-
C levels reduction between alirocumab and placebo 
(62%, p < 0.001), with the mean absolute reduction 
of 74 mg/dL (1.9 mmol/L) and 4 mg/dL (0.1 
mmol/L), respectively. This effect remained consistent 
over a period of 78 weeks. The percentage of patients 
with any adverse events was similar in the two groups 
(81% with alirocumab and 82.5% with placebo). Spe-
cific adverse events that were reported with higher 
rates in the alirocumab group involve injection-site 
reaction, myalgia, neurocognitive events (amnesia, 
memory impairment, confusional state) and ophthal-
mologic events (15). 
It should be noted that in a post hoc analysis 
there was a reduction in the rate of CV events (CV 
death, nonfatal myocardial infarction, fatal or non-
fatal ischemic stroke, unstable angina requiring hospi-
talization) in patients who received alirocumab (1.7%) 
compared to patients who received placebo (3.3%)  
(p = 0.02) (15). Given that the number of CV events 
was small, a follow-up period relatively short, and 
that post hoc analysis was applied, the obtained data 
must be confirmed additionally. 
ODYSSEY OUTCOMES trial will assess whether 
alirocumab significantly reduces CV morbidity and 
mortality in more than 18,000 patients with recent 
acute coronary syndrome. Results of the study are 
expected in 2018 (11). 
 
ApoB synthesis inhibitor – mipomersen 
  
Mipomersen was approved in the United States 
of America (USA) for treating patients with homozy-
gous FH as an addition to diet and maximally tole-
rated doses of statins and other lipid-lowering medi-
cations (16). However, in 2013, The Committee for 
Medicinal Products for Human Use (CHMP) of Euro-
pean Medicines Agency (EMA) recommended, for the 
second time, the refusal of the marketing authori-
sation for the mipomersen in European Union (EU). 
Reasons are as follows: a high proportion of patients 
stopped taking the medicine within two years (even 
in the group of patients with homozygous FH) mainly 
due to side effects, then, long-term consequences of 
a built-up of fat in the liver and increased enzyme 
levels and potential irreversible liver damage, as well 
as more CV events reported in patients taking this 
medicine (17).  
Mipomersen is a drug which can reduce LDL-C 
level by an additional 25% in homozygous FH pati-
ents when given in combination with maximum tole-
rated doses of lipid-lowering agents. It is an „anti 
sense” oligonucleotide, 20 nucleotides in length, de-
signed to block the production of apoB by attaching to 
the genetic material of cells responsible for produ-
cing it (Figure 2) (18).  
 
 
 
 
 
 
Figure 2. Mechanism of action of mipomersen and 
lomitapide 
apoB – apolipoprotein B;  
MTP - microsomal triglyceride transfer protein;  
VLDL - very low-density lipoproteins. 
 
 
 
ApoB is a crucial structural and functional component 
of all atherogenic lipoproteins. The human APOB gene 
encodes a single RNA transcript from which 2 iso-
forms, apoB-100 and apoB-48, are translated as a 
result of messenger RNA editing. ApoB-100, which is 
an essential structural component of very low-density 
lipoproteins (VLDL) and LDL-C, is produced predo-
minantly by hepatocytes, while apoB-48, which is an 
essential structural component of chylomicrons, is 
produced predominantly by enterocytes. Mipomer-
sen is complementary to the coding region of the 
messenger RNA for apo B-100. The hybridization of 
mipomersen to the target messen-ger RNA results in 
ribonuclease H1-mediated degradation of messenger 
RNK, leading to the reduction of apoB-100 produc-
tion and hence, synthesis of VLDL and LDL-C is redu-
ced (18, 19). 
It should be noted that apoB has been identi-
fied as a new risk factor for atherosclerosis develop-
ment. It is shown that apoB level is correlated to CV 
risk (19). The AMORIS study (Apolipoprotein-related 
MOrtality RISk study) indicated that elevated apoB is 
a more significant predictor of fatal myocardial infar-
ction than LDL-C alone (20).  
Mipomersen is administrated subcutaneously, 
usually in the dose of 200 mg once weekly. Following 
subcutaneous injection, maximal plasma concentra-
tions are reached in 3 to 4 hours, while bioavailability 
of mipomersen ranged from 54% to 78%. Mipomer-
sen is highly bound to human plasma proteins (≥ 
90%) and, with once weekly dosing, plasma levels 
approach steady state typically within 6 months. Eli-
mination half-life for mipomersen is approximately 1 
to 2 months. This drug is not a substrate for the 
CYP450 metabolism, so, there are no clinically rele-
57 
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vant pharmacokinetic interactions between mipomer-
sen and warfarin or between mipomersen and sim-
vastatin or ezetimibe (18). 
In clinical trials, mipomersen has been studied 
in healthy volunteers (21), in patients on statin the-
rapy (22, 23) and in patients with FH (24-26). 
In a study which involved 36 healthy volunteers 
with mild hypercholesterolemia, administration of mi-
pomersen in doses ranging from 50 to 200 mg for 4 
weeks, showed a dose-dependent and prolonged re-
duction in apoB and LDL-C with the maximum reduc-
tion from baseline of 50% and 35%, respectively, in 
the 200-mg dose group (21). In addition, a study 
(Dose-Escalating Safety Study in Subjects on Stable 
Statin Therapy) which involved 74 patients on stable 
statin therapy, showed that application of mipo-
mersen during 5 weeks reduced LDL-C levels ranged 
from 18% to 49% relative to the placebo-control 
group at doses of 100 mg and higher. Within this 
study, the reduction in apoB and LDL-C of 36% from 
baseline was demonstrated in a group of 12 patients 
treated with 200 mg mipomersen over 13 weeks, 
what is more significant than the effect observed in 
the same-dose 5-week treatment group (22). 
The efficacy of mipomersen therapy in patie-
nts with FH was confirmed in several phase II and III 
trials on the basis of which it is approved for this 
indication by the US Food and Drug Administration 
(FDA). For example, mipomersen was studied in pha-
se III trial which involved 51 patients with homozy-
gous FH already receiving maximum tolerated dose of 
lipid-lowering medications. The primary endpoint was 
percentage change in LDL-C concentration from base-
line. After 26 weeks, patients receiving 200 mg of 
mipomersen subcutaneously once weekly had more 
significant LDL-C reduction (-24.7%) compared with 
placebo (-3.3%, p = 0.0003). The most common ad-
verse events were injection site reactions (76% 
mipomersen vs. 24% placebo), and 4 patients (12%) 
receiving mipomersen had elevation in ALT ≥ 3x the 
upper limit of normal (21).  
The adverse reactions of mipomersen for 
pooled Phase III clinical trials are: injection site 
reactions (84%), flu-like symptoms (~ 30%, which 
typically occur within 2 days after an injection), 
elevations in serum transaminases (specifically ALT, 
~ 10%), hepatic steatosis (with or without conco-
mitants increases in transaminases), gastrointestinal 
(30%), neurological (25%) and psychiatric (10%) 
disorders. Due to the risk of hepatotoxicity, mipo-
mersen is available only trough a limited REMS (Risk 
Evaluation and Mitigation Strategy) program in 
which it could be prescribed and distributed only by 
certified physicians and pharmacists aiming to moni-
tor patients because of the risk of side effects (18).  
 
MTP inhibitor – lomitapide 
 
Lomitapide was approved in 2012 by FDA, in 
2013 by EMA, followed by marketing authorisation in 
Canada, Mexico, Taiwan and Japan for treating pati-
ents with homozygous FH as an addition to diet and 
maximum tolerated doses of statins and other lipid-
lowering medications (11, 27-29). In homozygous 
FH patients, lomitapide can additionally reduce LDL-
C levels by up to by 50%. 
Lomitapide is an orally active, small molecule 
that directly binds to MTP, a protein localized in an 
endoplasmic reticulum, the role of which is to tran-
sport triglycerides, phospholipids and cholesterol es-
ters to the newly synthesized apoB. This is a key 
step in the synthesis of VLDL in hepatocytes and 
chylimicrons in enterocytes (Figure 2) (30, 31). Inhi-
bition of this protein in hepatocytes leads to a de-
crease in the VLDL concentration in the circulation 
and, consequently, to a decrease in LDL-C (32). In 
addition, inhibition of MTP in enterocytes can reduce 
plasma triglyceride levels by reducing fat absorption 
from foods through chylomicron (1). 
After oral administration, the bioavailability of 
lomitapide is 7%, which is largely due to the extensive 
first pass effect. Maximum plasma concentrations 
were reached after 4-8 hours, and despite a high bin-
ding rate for plasma proteins (> 99.8%), it has a 
high volume of distribution. Lomitapide has an exten-
sive liver metabolism, predominantly via CYP450 3A4, 
while other isoforms (2E1, 1A2, 2B6, 2C8 and 2C19) 
are involved to a lesser extent. The elimination half-
life of lomitapide was approximately 29 hours. Be-
cause lomitapide is metabolized by CYP3A4, conco-
mitant use with strong or moderate CYP3A4 inhibitors 
(e.g., antifungal azoles such as itraconazole, flucona-
zole, ketoconazole, voriconazole, posaconazole; mac-
rolide antibiotics such as erythromycin or clarithro-
mycin; ketolide antibiotics such as telithromycin; HIV 
protease inhibitors; the calcium channel blockers dil-
tiazem and verapamil, and the anti-arrhythmic dro-
nedarone) is contraindicated.  
If treatment with these drugs is unavoidable, 
lomitapide should be stopped during the course of 
treatment. When administered with atorvastatin, a 
weak CYP3A4 inhibitor, the dose of lomitapide should 
either be taken 12 hours apart or be decreased by 
half. Lomitapide increases plasma concentrations of 
statins, which increases the risk of myopathy, requi-
ring additional caution and monitoring. Concomitant 
administration of > 40 mg simvastatin is contrain-
dicated. There is no need for dose adjustment in 
concomitant administration with fenofibrate, niacin 
or ezetimibe. Also, lomitapide increases the plasma 
concentration of warfarin, so regular monitoring of 
the INR (international normalized ratio) is recom-
mended. Simultaneous use of St. John’s Wort, gra-
pefruit and alcohol with this drug should be avoided, 
and it may affect the absorption of fat-soluble nu-
trients (e.g. vitamin E) (33). 
Lomitapide was studied in several phase II 
and III trials. For example, in the phase III HoFH 
Lomitapide Study, efficacy and safety of lomitapide 
was investigated in 29 patients with homozygous FH 
receiving appropriate lipid-lowering therapy. The pri-
mary endpoint was mean percent change in levels of 
LDL-C from baseline to week 26, after which patients 
remained on lomitapide through to week 78 for safety 
assessment. Lomitapide, at median dose of 40 mg (a 
starting dose was 5 mg and then escalated to the 
maximum of 60 mg), reduced LDL-C by 50%, from 
8.7 mmol/L at baseline to 4.3 mmol/L after 26 weeks 
(p < 0.0001). Concentrations of LDL-C remained re-
duced by 44% (p < 0.0001) at week 56 and 38%  
(p < 0.0001) at week 78. Changes in levels of total 
cholesterol, apoB and triglycerides were similar with 
8 
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change in LDL-C. During this study, side effects of 
lomitapide were mainly related to the gastrointesti-
nal system. Four patients had AST/ALT > 5x the 
upper limit of normal, which resolved after dose redu-
ction or temporary interruption of lomitapide, but 
there were no permanent discontinuation of treat-
ment because of liver abnormalities (34). 
The most serious adverse reactions during tre-
atment with lomitapide were just liver aminotransfe-
rase abnormalities. Hepatic steatosis (with or without 
concomitants increases in transaminases) is also re-
ported, and because of the risk of hepatotoxicity, like 
mipomersen, it is available trough the REMS pro-
gram (33). 
The most common adverse events of lomita-
pide, reported by 93% of patients, were gastroin-
testinal. Among them, diarrhoea occurred in 79% of 
patients, nausea in 65%, dyspepsia in 38%, vomit-
ing in 34%, while flatulence, constipation and abdo-
minal pain were reported by at least 20% of patie-
nts. These side effects are the result of its mecha-
nism of action, and may affect the absorption of the 
concomitantly administered oral drugs (33). 
Due to the fetal toxicity, based on findings of 
teratogenicity animals, females of reproductive pote-
ntial should have a negative pregnancy test before 
starting lomitapide and use contraception during 
treatment (33). 
 
Bempedoic acid 
  
Bempedoic acid is a novel, oral LDL-C lowering 
drug that significantly reduces elevated LDL-C levels 
in patients with hypercholesterolemia, including pa-
tients inadequately treated with current lipid-modi-
fying therapies. It works in the liver to block chole-
sterol biosynthesis by direct ATP citrate lyase (ACL) 
inhibition, a key enzyme that supplies substrate for 
cholesterol and fatty acid synthesis in the liver, re-
sulting in up-regulation of LDL receptor (35).  
To date, bempedoic acid has been studied in 
eighteen completed Phase 1 and Phase 2 clinical stu-
dies which showed clinically relevant LDL-C lowering 
results of up to 30%  as monotherapy, approxima-
tely 50% in combination with ezetimibe, and an in-
cremental 20% + when added to stable statin therapy 
(any statin at any dose). Currently, bempedoic acid is 
evaluated in four global Phase 3 LDL-C lowering 
efficacy and safety studies on approximately 3,200 
patients at high CV risk with hypercholesterolemia 
on optimized background lipid-modifying therapy, 
and one cardiovascular outcomes trial (Cholesterol 
Lowering via BEmpedoic Acid, an ACL-inhibiting Re-
gimen (CLEAR) Outcomes) which is expected to enrol 
approximately 12,600 patients in approximately 30 
countries (35, 36). In addition, initiation of a single 
global Phase 3 bridging study (1002FDC-053), to 
evaluate the efficacy and safety of the bempedoic 
acid / ezetimibe combination, is planned and it is 
expected to enroll up to 350 patients (37). Results of 
Phase III program are expected during 2018 (36, 
37). 
CETP inhibitors 
 
In recent years, extensive research is being 
carried out to identify new HDL-raising drugs hoping 
that this would lead to further reduction of cardio-
vascular risk. Currently, CETP inhibitors are being 
actively studied for that purpose (38). 
The role of CETP is to promote the transfer of 
cholesteryl esters between plasma lipoproteins, there-
fore, CETP inhibition raises HDL-C levels and decrea-
ses LDL-C levels (Figure 3) (39). Epidemiological data 
have clearly demonstrated a strong inverse rela-
tionship between HDL-C levels and the risk of CV 
events (40-42). 
 
 
 
 
 
 
Figure 3. Mechanism of action of CETP  
(cholesteryl ester transfer protein) inhibitors 
VLDL – very low-density lipoproteins;  
IDL – intermediate density lipoprotein;  
LDL - low-density lipoproteins;  
HDL – high-density lipoproteins;  
CE - cholesteryl esters; TG – triglyceride. 
 
 
 
Torcetrapib, dalcetrapib, evacetrapib and ana-
cetrapib are CETP inhibitors reaching phase III clinical 
trials. However, the torcetrapib trial was terminated 
prematurely because of mortality increase (CV and 
overall). Since the increase in mortality and increase 
in blood pressure (5.4 mmHg) was probably not cau-
sed by mechanism of action of torcetrapib, but, at 
least in part, by increased level of aldosterone as 
well as plasma electrolyte composition changes - 
lower potassium levels and increased sodium and 
bicarbonate levels (43), the testing of new CETP 
inhibitors is continued. Trials with dalcetrapib and 
evacetrapib were terminated due to insufficient effi-
cacy. Although these drugs significantly raised HDL-C 
level, they failed to show a significant reduction in 
cardiovascular events (44, 45). Effects of anacetrapib 
on cardiovascular outcomes are currently being eva-
luated in the ongoing REVEAL (Randomized Eva-
luation of the Effects of Anacetrapib through Lipid 
Modification) trial, a phase III trial on over 30,000 
patients with atherosclerotic vascular disease who 
were receiving intensive atorvastatin therapy. Altho-
ugh the study completion is planned for 2019, the 
first results, after the median follow-up period of 4.1 
years, showed that the addition of anacetrapib to 
intensive statin therapy resulted in a lower incidence 
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of major coronary events (coronary death, myo-
cardial infarction, coronary revascularization) than 
the addition of placebo, despite very well-controlled 
baseline LDL cholesterol levels. The proportional risk 
reductions appeared to be larger with more prolong-
ed follow-up. Anacetrapib did not affect the mortality 
rate (from cardiovascular or non-cardiovascular cau-
ses), the incidence of cancer, or any significant exces-
ses in any major category of the adverse events. 
Patients who received anacetrapib had slightly higher 
blood pressure levels (0.7 mmHg systolic and 0.3 
mmHg diastolic) compared to the placebo group, but 
there was no difference in the rate of adverse effects 
associated with hypertension. Also, there were slightly 
higher rates of moderate elevations in creatine kinase 
in the anacetrapib group than in the placebo group, 
but slightly lower rates of more severe elevations (> 
40 times the upper limit of the normal range) (46). 
Results of this trial are expected to provide a final 
answer to the question whether CETP inhibitors might 
actually be effective for the reduction of cardiovas-
cular risk or further investigation of this group of 
drugs should be discontinued. 
 
Conclusion 
 
Results of numerous clinical studies conducted 
during the past three decades clearly show that 
statin therapy significantly reduces the level of LDL-C 
as well as the occurrence of CV events and mortality. 
However, a significant number of patients using sta-
tins do not achieve the desired levels of LDL-C, 
especially those with high or very high CV risk. In 
addition, patients intolerant of statins should also be 
mentioned, as well as those with contraindications to 
these drugs. For these reasons, there is a need for 
some new lipid-lowering agents in therapy, which 
will further reduce not only the level of LDL-C, but 
also the occurrence of CV events. 
Currently, the most promising agents are 
PCSK9 inhibitors. It has been shown that they pro-
duce significant LDL-C level reduction, and that they 
are well tolerated by patients. They are approved for 
use in combination with statins for the treatment of 
heterozygous FH, and in patients with clinical athero-
sclerotic CV diseases. In addition, evolocumab is 
approved for use in patients with homozygous FH. 
Mipomersen, apoB synthesis inhibitor, and lo-
mitapide, an oral MTP inhibitor, are currently approv-
ed, for treating patients with homozygous FH as an 
addition to statins and other lipid-lowering medica-
tions. Their usage is significantly limited by the high 
risk of hepatotoxicity. 
Although the new lipid-lowering agents produce 
significant LDL-C level reduction, it is necessary to 
conduct longer trials with more patients, confirming 
their efficacy and safety, thus enabling their wider 
use for the treatment of dyslipidemia. 
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Dislipidemije su vodeći faktor rizika za razvoj ateroskleroze i njenih posledica, kao što 
su koronarna bolest srca, ishemična cerebrovaskularna i periferna vaskularna bolest. Ove 
bolesti su glavni uzrok mortaliteta, kako u svetu tako i u Evropi, gde su odgovorne za 45% 
ukupne smrtnosti. Terapija dislipidemija uključuje primenu: statina, ezetimiba, fibrata, 
niacina, smola koje vezuju žučne kiseline i omega-3 masnih kiselina. Od pomenutih lekova, 
vodeću ulogu u terapiji dislipidemija imaju statini. Treba istaći da uprkos primeni statina, koji 
redukuju rizik od pojave kardiovaskularnih (KV) događaja za oko 30%, još uvek ostaje tzv. 
rezidualni rizik za nastanak KV događaja, što ukazuje da su potrebni novi lekovi koji će dalje 
redukovati rezidualni rizik. Novi lekovi u terapiji dislipidemija uključuju PCSK9 inhibitore, 
inhibitore sinteze apolipoproteina B (apoB), MTP inhibitore i CETP inhibitore, koji su ili već 
odobreni za primenu u određenim indikacijama, ili se nalaze u odmaklim fazama kliničkog 
ispitivanja. Alirokumab i evolokumab, dva PCSK9 inhibitora, odobrena su za primenu, u 
kombinaciji sa statinima, u terapiji heterozigotne familijarne hiperholesterolemije (FH), kao i 
kod bolesnika sa kliničkim aterosklerotičnim KV bolestima koji zahtevaju dodatnu redukciju 
nivoa lipoproteina male gustine (low-density lipoprotein cholesterol, LDL-C). Pored toga, 
evolokumab je odobren za primenu kod bolesnika sa homozigotnom FH. Mipomersen, 
inhibitor sinteze apoB, i lomitapid, oralni MTP inhibitor, su, odobreni za primenu samo kod 
bolesnika sa homozigotnom FH kao dodatak maksimalnoj tolerišućoj dozi statina i drugih 
hipolipemika. Iako novi hipolipemici značajno redukuju nivo LDL-C, neophodno je sprovesti 
studije, duže i sa većim brojem ispitanika, koje će potvrditi njihovu efikasnost i bezbednost i 
time omogućiti njihovu širu primenu u terapiji dislipidemija. 
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